Every May, the awareness campaigns arrive on schedule. The green ribbons. The social media graphics. The wellness emails from HR. Mental Health Awareness Month has been observed since Mental Health America founded it in 1949, and the 2026 theme, “More Good Days, Together,” is a beautiful idea worth taking seriously.
But it raises a quiet question: more good days for whom, and through what kind of care?
If you’ve been struggling with depression for a while, you probably already know the awareness piece. You know depression is real. You know it’s common. You may have already seen a doctor, tried a medication or two (or three), and still feel like the good days are too few and too far between.
This article isn’t about awareness in the abstract. It’s about what to do when awareness alone hasn’t moved the needle, and what modern, evidence-based depression care looks like when standard treatments haven’t worked.
The Gap Awareness Alone Can’t Close
The scale of mental illness in the United States isn’t a mystery. According to the National Institute of Mental Health, an estimated 59.3 million U.S. adults (roughly one in five) lived with any mental illness in the most recent national survey year, and roughly 14.6 million experienced serious mental illness, the kind that disrupts daily life, work, and relationships. (Figures reflect NIMH’s published NSDUH estimates as of 2026.)
Depression is at the center of that picture. The World Health Organization names it a leading cause of disability worldwide, and NIMH identifies it as the leading cause of disability for U.S. adults aged 15–44. The economic burden of major depressive disorder reached an estimated $326.2 billion in 2018, most of it tied to lost productivity at work.
These numbers aren’t here to overwhelm you. They’re here to make a simple point: if you’re struggling, you’re not alone, and you’re not failing at being a person. Depression is a medical condition with a real cost: to lives, to families, to entire communities.
The harder truth is that awareness, on its own, hasn’t closed the gap between diagnosis and recovery. The 2026 Mental Health Awareness Month story isn’t really about people who don’t know they’re depressed. It’s about people who have been diagnosed, treated with standard medications, and are still waiting to feel like themselves again.
When the Standard Treatment Path Hasn’t Worked
If you’ve been prescribed an antidepressant that didn’t help, then a second one, then maybe a third, you already know the shape of this story. There’s a clinical name for the pattern, sequential trial-and-error, and the data behind it comes from the largest depression treatment study ever done in the U.S.
The NIMH-funded STAR*D trial followed 4,041 adults with major depressive disorder as they tried up to four medication strategies. The results tell a story many patients recognize:
- Step 1 (typically an SSRI like citalopram): about 37% reached remission
- Step 2 (switching or adding a medication): about 31% reached remission
- Step 3 (another switch or addition): about 14% reached remission
- Step 4 (further combinations): about 13% reached remission
Each step took an average of six to twelve weeks. By the end of the study, roughly two-thirds of participants had reached remission across all four steps, which means nearly one in three never did, even after trying everything the standard ladder had to offer.
If you’re in that group, please hear this clearly: it’s not because you didn’t try hard enough. It’s not a flaw in your willpower or your character. The standard medication ladder was built for an earlier era of psychiatry, when SSRIs and SNRIs were essentially the only tools available. For the people who don’t respond to those tools, the answer isn’t more of the same. It’s a different kind of care.
What Modern Depression Care Actually Looks Like
The good news (and there is good news) is that depression treatment has moved well beyond the standard pill-trial ladder. Interventional psychiatry, a category of treatments that work on the brain through different mechanisms than traditional antidepressants, is now considered standard of care for treatment-resistant depression (TRD), generally defined as depression that hasn’t responded to at least two adequate antidepressant trials.
Four modalities form the backbone of modern, multi-modal depression care:
IV ketamine is given as a slow infusion in a medical setting, working through the brain’s glutamate system rather than serotonin. A typical course is six infusions over three to six weeks. Many people notice mood changes within hours to days, a striking shift compared to the weeks SSRIs require.
Spravato (esketamine) is the FDA-approved nasal spray version of ketamine, cleared for treatment-resistant depression in March 2019. It’s given on-site under observation, usually starting twice weekly for a month and then tapering.
Ketamine-assisted psychotherapy (KAP) pairs medical ketamine with structured therapy: preparation before the session, integration after. This is the modality for people who want to do deeper psychological work alongside the pharmacological lift.
TMS (transcranial magnetic stimulation) uses gentle magnetic pulses to stimulate the prefrontal cortex over a series of sessions. Newer accelerated protocols can compress weeks of treatment into days. For more on what those look like, see our guide to TMS for treatment-resistant depression in Manhattan.
The most important thing to know about these options isn’t which one is “best.” It’s whether your treatment team can move between them based on how you respond, without referring you out, restarting your intake somewhere new, or losing the thread of who you are and what you’ve already tried.
Why the Care Model Matters as Much as the Treatment
A treatment is only as good as the team behind it. For someone with TRD, the most important question often isn’t “which modality should I try?” It’s “who’s going to manage my care if the first thing doesn’t fully work?”
This is the structural problem most clinics weren’t built to solve. Many specialty practices offer one modality. If it works, wonderful. If it only partially works, you’re handed a referral to a different clinic with different staff, and you start over: new intake, new history, new wait list, new copays.
That’s a lot to ask of someone who’s already exhausted.
What integrated, same-roof care offers is the opposite of fragmentation: one psychiatric team that owns your full plan from evaluation through treatment through maintenance. If IV ketamine brings real but partial relief, the same team can layer in TMS, or shift to Spravato, without re-explaining your story to a stranger. For more on how that combined approach works in practice, our guide to integrated TMS and ketamine treatment walks through the sequencing options.
That continuity is what the 2026 theme, “More Good Days, Together,” actually requires. Together, in this context, means a treatment team that stays with you.
Five Questions Worth Asking Any Mental Wellness & Healing Center
If this Mental Health Awareness Month is the moment you’re researching options for yourself or someone you love, bring these questions to any provider you consider:
| Question | Why It Matters |
|---|---|
| Do you offer all four interventional modalities (IV ketamine, Spravato, KAP, and TMS) or do you refer out for some? | Referrals create gaps. Each handoff costs time and information. |
| What happens if the first modality doesn’t bring full remission? | You’re looking for a clinic that has a plan, not a hope. |
| Does one psychiatric team own my full plan, or is each treatment managed by a different provider? | Fragmented oversight is the most common reason people fall through the cracks. |
| What’s covered by insurance versus self-pay? | Spravato and standard TMS often have insurance pathways. IV ketamine and accelerated TMS protocols typically don’t. You deserve clarity up front. |
| Who’s responsible for me after the initial course ends? | Recovery doesn’t stop at the last session. Ask about the long arc. |
These aren’t trick questions. They’re designed to surface whether a clinic can deliver the kind of coordinated, flexible, multi-step care that the STAR*D data, and your lived experience, say is actually needed.
A Place to Start When You’re Ready
Nushama is an interventional psychiatry center in Manhattan, on the 21st floor of 515 Madison Avenue. We run all four interventional modalities (IV ketamine, Spravato, KAP, and accelerated TMS) under one psychiatric team. That structure is what lets us sequence treatment without sending you somewhere else when one path needs to expand into another.
For Mental Health Awareness Month, we’re offering a free 15-minute consultation with an interventional psychiatrist. No pressure, no commitment. Just a conversation about what your options actually are, what’s likely to be covered by your insurance, and what a thoughtful next step might look like.
If you’ve been living with depression that hasn’t responded to standard treatment, or if you’re a partner, parent, or friend trying to help someone who is, this is the kind of conversation that can shift the path. More good days are possible. They just usually take more than awareness alone to reach.
Book a Mental Health Awareness Month consultation
Frequently Asked Questions
What is Mental Health Awareness Month 2026’s theme?
Mental Health America’s 2026 theme is “More Good Days, Together.” It encourages communities and individuals to focus on increasing the days that feel manageable and meaningful, with an emphasis on connection and supportive care.
What is interventional psychiatry?
Interventional psychiatry refers to treatments that work on the brain through mechanisms different from traditional oral antidepressants. It includes IV ketamine, Spravato (esketamine), ketamine-assisted psychotherapy, and transcranial magnetic stimulation (TMS). These options can help people with treatment-resistant depression who haven’t responded to standard medications.
How do I know if I have treatment-resistant depression?
Treatment-resistant depression (TRD) is generally defined as depression that hasn’t improved after at least two different antidepressants taken at adequate doses for adequate durations. If you’ve been through multiple medication trials without reaching remission, a consultation with an interventional psychiatrist can help clarify your options.
Where can I find interventional psychiatry in Manhattan?
Nushama, located at 515 Madison Avenue (21st floor), offers IV ketamine, Spravato, ketamine-assisted psychotherapy, and accelerated TMS, all coordinated by one psychiatric team.
